OS Therapies Inc (OSTX)
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Grasonville, Maryland.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
OS Therapies Incorporated
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
USOS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States.
Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Grasonville, Maryland.
Leadership
Avril McKean Dieser
Director
Christopher P. Acevedo
Chief Financial Officer
Craig Eagle, M.D.
Director
Gerald Commissiong
Chief Business Officer
Employees
5
Country
US
Sector
Healthcare
Website
ostherapies.com
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 McKean-Dieser Avril Suzette | Director | Grant/Award | 50.0K | -- | Jan 22, 2026 |
 Search Theodore F. | Director | Grant/Award | 50.0K | -- | Jan 22, 2026 |
 Galzahr Karim | Director | Grant/Award | 50.0K | -- | Jan 22, 2026 |
 Jarry Olivier Roger | Director | Grant/Award | 50.0K | -- | Jan 22, 2026 |
 Romness Paul A. | President and CEO | Grant/Award | 1.00M | -- | Jan 22, 2026 |
 PETIT ROBERT | See Remarks | Grant/Award | 100.0K | -- | Jan 22, 2026 |
| Name | Shares | % | Source |
|---|---|---|---|
Thomas A. Satterfield, Jr. · may incl. warrants· filed Aug 2025 | 3.1M | 6.7% | 13G |
Shalom Auerbach · may incl. warrants· filed Aug 2025 | 2.7M | 5.7% | 13D |
 Romness Paul A. President and CEO, Director | 2.2M | 4.8% | FORM 4 |
AYALA PHARMACEUTICALS, INC. · may incl. warrants· filed Apr 2025 | 2.2M | 4.6% | 13G |
VANGUARD CAPITAL MANAGEMENT LLC | 777.7K | 1.7% | 13F |
CM Management, LLC | 400.0K | 0.9% | 13F |
GEODE CAPITAL MANAGEMENT, LLC | 301.8K | 0.6% | 13F |
HOWARD FINANCIAL SERVICES, LTD. | 248.0K | 0.5% | 13F |
BlackRock, Inc. | 242.5K | 0.5% | 13F |
 PETIT ROBERT See Remarks | 200.0K | 0.4% | FORM 4 |
Insiders
- McKean-Dieser Avril SuzetteDirector
- Search Theodore F.Director
- Galzahr KarimDirector
- Jarry Olivier RogerDirector
- Romness Paul A.President and CEO
- PETIT ROBERTSee Remarks
- Acevedo Christopher P.Chief Financial Officer
- Ciccio JohnDirector
- Auerbach Shalom10% Owner
- GODDARD COLINDirector
US30d Avg
695.41K
60d Avg
730.03K
90d Avg
596.47K